drug1_db stringlengths 7 7 | drug2_db stringlengths 7 7 | drug1_id int64 0 1.69k | drug2_id int64 0 1.69k | drug_pair listlengths 2 2 | drug1_name stringlengths 4 85 | drug2_name stringlengths 4 85 | drug1_desc stringlengths 27 1.09k | drug2_desc stringlengths 27 6.14k | label stringclasses 3
values | label_idx int64 0 2 | all_paths listlengths 1 10 | all_paths_str listlengths 1 10 | path_str stringlengths 0 3.57k |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00220 | DB09030 | 798 | 840 | [
"DDInter1276",
"DDInter1945"
] | Nelfinavir | Vorapaxar | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
798,
25,
840
]
],
[
[
798,
25,
1017
],
[
1017,
63,
840
]
],
[
[
798,
24,
1496
],
[
1496,
63,
840
]
],
[
[
798,
25,
578
],
[
578,
... | [
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} ma... | Nelfinavir may lead to a major life threatening interaction when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Nintedanib and Nintedanib may cause a... |
DB01234 | DB01276 | 1,220 | 123 | [
"DDInter513",
"DDInter706"
] | Dexamethasone | Exenatide | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Exenatide is a glucagon-like peptide-1 (GLP-1) analog. It activates the GLP-1 receptor and increases insulin secretion, decreases glucagon secretion, and slows gastric emptying to improve glycemic control. Exenatide was given FDA approval on April 28, 2005. It is available as immediate- and extended-release formulation... | Moderate | 1 | [
[
[
1220,
24,
123
]
],
[
[
1220,
63,
1252
],
[
1252,
23,
123
]
],
[
[
1220,
40,
1103
],
[
1103,
23,
123
]
],
[
[
1220,
62,
1072
],
[
1072,... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
]
],
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
... | Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Exenatide
Dexamethasone (Compound) resembles Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit c... |
DB00557 | DB08871 | 252 | 36 | [
"DDInter895",
"DDInter666"
] | Hydroxyzine | Eribulin | Hydroxyzine is a first-generation histamine H<sub>1</sub>-receptor antagonist of the dephenylmethane and piperazine classes that exhibits sedative, anxiolytic, and antiemetic properties.[A1257,A187589] It was first developed in 1955, and has since remained a relatively common treatment for allergic conditions such as p... | Eribulin is a microtubule inhibitor indicated for the treatment of patients with metastatic breast cancer who have previously received at least two chemotherapeutic regimens for the treatment of metastatic disease. Eribulin was isolated from the marine sponge Halichondria okadai. Eribulin is also being investigated for... | Moderate | 1 | [
[
[
252,
24,
36
]
],
[
[
252,
63,
1424
],
[
1424,
24,
36
]
],
[
[
252,
24,
820
],
[
820,
24,
36
]
],
[
[
252,
24,
28
],
[
28,
63,
... | [
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
]
],
[
[
"Hydroxyzine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
... | Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Eribulin
Hydroxyzine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine... |
DB00624 | DB01259 | 1,561 | 392 | [
"DDInter1776",
"DDInter1024"
] | Testosterone (topical) | Lapatinib | Testosterone is an androstanoid having 17beta-hydroxy and 3-oxo groups, together with unsaturation at C-4-C-5.. It has a role as an androgen, a human metabolite, a Daphnia magna metabolite and a mouse metabolite. It is a 17beta-hydroxy steroid, an androstanoid, a C19-steroid and a 3-oxo-Delta(4) steroid. | Lapatinib is an anti-cancer drug developed by GlaxoSmithKline (GSK) as a treatment for solid tumours such as breast and lung cancer. It was approved by the FDA on March 13, 2007, for use in patients with advanced metastatic breast cancer in conjunction with the chemotherapy drug capecitabine. Lapatinib is a human epide... | Moderate | 1 | [
[
[
1561,
24,
392
]
],
[
[
1561,
10,
11579
],
[
11579,
44,
392
]
],
[
[
1561,
6,
4973
],
[
4973,
45,
392
]
],
[
[
1561,
21,
29429
],
[
294... | [
[
[
"Testosterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
]
],
[
[
"Testosterone",
"{u} (Compound) palliates {v} (Disease)",
"breast cancer"
],
[
"breast cancer",
"{u} (Disease) i... | Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Testosterone (Compound) palliates breast cancer (Disease) and breast cancer (Disease) is treated by Lapatinib (Compound)
Testosterone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Lapatinib (Compound)
Tes... |
DB00911 | DB00951 | 458 | 1,072 | [
"DDInter1811",
"DDInter986"
] | Tinidazole | Isoniazid | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Antibacterial agent used primarily as a tuberculostatic. It remains the treatment of choice for tuberculosis. | Moderate | 1 | [
[
[
458,
24,
1072
]
],
[
[
458,
6,
8374
],
[
8374,
45,
1072
]
],
[
[
458,
21,
28722
],
[
28722,
60,
1072
]
],
[
[
458,
63,
896
],
[
896,
... | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
]
],
[
[
"Tinidazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Tinidazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Isoniazid (Compound)
Tinidazole (Compound) causes Nausea (Side Effect) and Nausea (Side Effect) is caused by Isoniazid (Compound)
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may... |
DB00635 | DB01018 | 1,573 | 1,364 | [
"DDInter1515",
"DDInter847"
] | Prednisone | Guanfacine | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approva... | Moderate | 1 | [
[
[
1573,
24,
1364
]
],
[
[
1573,
63,
1512
],
[
1512,
1,
1364
]
],
[
[
1573,
6,
10215
],
[
10215,
45,
1364
]
],
[
[
1573,
21,
28757
],
[
2... | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Guanfacine"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
... | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac (Compound) resembles Guanfacine (Compound)
Prednisone (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Guanfacine (Compound)
Prednisone (Compound) causes Dyspepsia (Side Effect) and Dyspeps... |
DB04575 | DB11827 | 35 | 433 | [
"DDInter1555",
"DDInter669"
] | Quinestrol | Ertugliflozin | The 3-cyclopentyl ether of ethinyl estradiol. | Ertugliflozin is a sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor used to treat type II diabetes mellitus. It works to block glucose reabsorption from the glomerulus. Ertugliflozin was first approved by the FDA in December 2017.[A261951, L1132] It was also approved by the European Commission in March 2018. | Moderate | 1 | [
[
[
35,
24,
433
]
],
[
[
35,
63,
959
],
[
959,
24,
433
]
],
[
[
35,
40,
1438
],
[
1438,
24,
433
]
],
[
[
35,
1,
1336
],
[
1336,
24,
... | [
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ertugliflozin"
]
],
[
[
"Quinestrol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
... | Quinestrol may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin
Quinestrol (Compound) resembles Estradiol (Compound) and Estradiol may cause a moderate interaction that could ... |
DB00205 | DB01157 | 929 | 304 | [
"DDInter1550",
"DDInter1875"
] | Pyrimethamine | Trimetrexate | One of the folic acid antagonists that is used as an antimalarial or with a sulfonamide to treat toxoplasmosis. | A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against pneumocystis pneumonia in AIDS patients. Myelosuppression is its dose-limiting toxic effect. | Moderate | 1 | [
[
[
929,
24,
304
]
],
[
[
929,
24,
1548
],
[
1548,
40,
304
]
],
[
[
929,
6,
2946
],
[
2946,
45,
304
]
],
[
[
929,
21,
28784
],
[
28784,
... | [
[
[
"Pyrimethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimetrexate"
]
],
[
[
"Pyrimethamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trimethoprim"
]... | Pyrimethamine may cause a moderate interaction that could exacerbate diseases when taken with Trimethoprim and Trimethoprim (Compound) resembles Trimetrexate (Compound)
Pyrimethamine (Compound) binds DHFR (Gene) and DHFR (Gene) is bound by Trimetrexate (Compound)
Pyrimethamine (Compound) causes Thrombocytopenia (Side E... |
DB00536 | DB00804 | 1,225 | 1,507 | [
"DDInter848",
"DDInter543"
] | Guanidine | Dicyclomine | A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatmen... | Dicyclomine is a muscarinic M1, M3, and M2 receptor antagonist as well as a non-competitive inhibitor of histamine and bradykinin used to treat spasms of the intestines seen in functional bowel disorder and irritable bowel syndrome.[A6556,A182555,A234659,L7967] Though it is commonly prescribed, its recommendation may h... | Moderate | 1 | [
[
[
1225,
24,
1507
]
],
[
[
1225,
21,
28893
],
[
28893,
60,
1507
]
],
[
[
1225,
63,
19
],
[
19,
24,
1507
]
],
[
[
1225,
24,
85
],
[
85,
... | [
[
[
"Guanidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dicyclomine"
]
],
[
[
"Guanidine",
"{u} (Compound) causes {v} (Side Effect)",
"Hallucination"
],
[
"Hallucination",
"{u} (Side Effect) ... | Guanidine (Compound) causes Hallucination (Side Effect) and Hallucination (Side Effect) is caused by Dicyclomine (Compound)
Guanidine may cause a moderate interaction that could exacerbate diseases when taken with Hyoscyamine and Hyoscyamine may cause a moderate interaction that could exacerbate diseases when taken wit... |
DB00040 | DB00328 | 27 | 831 | [
"DDInter827",
"DDInter921"
] | Glucagon | Indomethacin | Glucagon is a 29 amino acid hormone used as a diagnostic aid in radiologic exams to temporarily inhibit the movement of the gastrointestinal tract and to treat severe hypoglycemia.[L7634,L7637,L7640,L7643,L8519] Glucagon raises blood sugar through activation of hepatic glucagon receptors, stimulating glycogenolysis and... | Indometacin, or indomethacin, is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic, and antipyretic properties. NSAIDs consist of agents that are structurally unrelated; the NSAID chemical classification of indometacin is an indole-acetic acid derivative with the chemical name 1- (p-chlor... | Moderate | 1 | [
[
[
27,
24,
831
]
],
[
[
27,
23,
126
],
[
126,
64,
831
]
],
[
[
27,
23,
699
],
[
699,
6,
4973
],
[
4973,
45,
831
]
],
[
[
27,
23,
... | [
[
[
"Glucagon",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indomethacin"
]
],
[
[
"Glucagon",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"W... | Glucagon may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Indomethacin
Glucagon may cause a minor interaction that can limit clinical effects when taken with Nadolol and Nadolol (Compound) binds ABCB1 (Ge... |
DB01166 | DB12010 | 477 | 214 | [
"DDInter379",
"DDInter785"
] | Cilostazol | Fostamatinib | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both prim... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
477,
24,
214
]
],
[
[
477,
64,
723
],
[
723,
24,
214
]
],
[
[
477,
63,
51
],
[
51,
24,
214
]
],
[
[
477,
25,
924
],
[
924,
24,
... | [
[
[
"Cilostazol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Aprepitant"
],
[
"Aprepita... | Cilostazol may lead to a major life threatening interaction when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Cilostazol may cause a moderate interaction that could exacerbate diseases when taken with Daunorubicin and Daunorubicin may ... |
DB00701 | DB01278 | 1,091 | 1,021 | [
"DDInter90",
"DDInter1506"
] | Amprenavir | Pramlintide | Amprenavir is a protease inhibitor used to treat HIV infection. | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Moderate | 1 | [
[
[
1091,
24,
1021
]
],
[
[
1091,
24,
1142
],
[
1142,
24,
1021
]
],
[
[
1091,
63,
1573
],
[
1573,
24,
1021
]
],
[
[
1091,
25,
1019
],
[
10... | [
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
]
],
[
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
],
[
... | Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Orlistat and Orlistat may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide
Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Prednisone and Prednison... |
DB00083 | DB00434 | 677 | 13 | [
"DDInter225",
"DDInter459"
] | Botulinum toxin type A | Cyproheptadine | In 2002, botulinum toxin A, also known as onabotulinumtoxinA or Botox, was the first type A botulism toxin to be introduced into the market for cosmetic use. With a wide variety of applications and favourable safety profile, Botulinum toxin A injection is a minimally invasive and promising treatment for cosmetic imperf... | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | Moderate | 1 | [
[
[
677,
24,
13
]
],
[
[
677,
24,
104
],
[
104,
63,
13
]
],
[
[
677,
24,
352
],
[
352,
24,
13
]
],
[
[
677,
24,
104
],
[
104,
1,
... | [
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
]
],
[
[
"Botulinum toxin type A",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
... | Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Botulinum toxin type A may cause a moderate interaction that could exacerbate diseases when ... |
DB00023 | DB00959 | 305 | 1,486 | [
"DDInter127",
"DDInter1191"
] | Asparaginase Escherichia coli | Methylprednisolone | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Moderate | 1 | [
[
[
305,
24,
1486
]
],
[
[
305,
24,
175
],
[
175,
40,
1486
]
],
[
[
305,
24,
167
],
[
167,
1,
1486
]
],
[
[
305,
24,
1072
],
[
1072,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone an... |
DB01234 | DB09263 | 1,220 | 1,436 | [
"DDInter513",
"DDInter1399"
] | Dexamethasone | Patiromer | Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [... | Patiromer is a powder for suspension in water for oral administration, approved in the U.S. as Veltassa in October, 2015. Patiromer is supplied as patiromer sorbitex calcium which consists of the active moiety, patiromer, a non-absorbed potassium-binding polymer, and a calcium-sorbitol counterion. Each gram of patirome... | Moderate | 1 | [
[
[
1220,
24,
1436
]
],
[
[
1220,
40,
870
],
[
870,
24,
1436
]
],
[
[
1220,
23,
1114
],
[
1114,
63,
1436
]
],
[
[
1220,
63,
1645
],
[
1645... | [
[
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Patiromer"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may ... | Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Patiromer
Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Zinc sulfate and Zinc sulfate may cause a moderate inter... |
DB00402 | DB12010 | 1,407 | 214 | [
"DDInter685",
"DDInter785"
] | Eszopiclone | Fostamatinib | Eszopiclone, marketed by Sepracor under the brand-name Lunesta, is a nonbenzodiazepine hypnotic drug used to treat insomnia. It is the active stereoisomer of zopiclone, belonging to the class of drugs known as _cyclopyrrolones_.[A179638,L6850] Cyclopyrrolone drugs demonstrate high efficacy and low toxicity, offering a ... | Fostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP [L2644, FDA Label]. Fostamatinib has also been granted orphan drug status by the FDA . Recently, fost... | Moderate | 1 | [
[
[
1407,
24,
214
]
],
[
[
1407,
24,
723
],
[
723,
24,
214
]
],
[
[
1407,
63,
600
],
[
600,
24,
214
]
],
[
[
1407,
24,
1017
],
[
1017,
... | [
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
]
],
[
[
"Eszopiclone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
... | Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib
Eszopiclone may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and F... |
DB01125 | DB09030 | 279 | 840 | [
"DDInter98",
"DDInter1945"
] | Anisindione | Vorapaxar | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagu... | Vorapaxar is a tricyclic himbacine-derived selective inhibitor of protease activated receptor (PAR-1) indicated for reducing the incidence of thrombotic cardiovascular events in patients with a history of myocardial infarction (MI) or with peripheral arterial disease (PAD). By inhibiting PAR-1, a thrombin receptor expr... | Major | 2 | [
[
[
279,
25,
840
]
],
[
[
279,
24,
885
],
[
885,
24,
840
]
],
[
[
279,
63,
714
],
[
714,
24,
840
]
],
[
[
279,
24,
1496
],
[
1496,
6... | [
[
[
"Anisindione",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vorapaxar"
]
],
[
[
"Anisindione",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epopros... | Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Vorapaxar
Anisindione may cause a moderate interaction that could exacerbate diseases when taken with Iloprost and Ilo... |
DB01181 | DB11988 | 1,532 | 270 | [
"DDInter906",
"DDInter1321"
] | Ifosfamide | Ocrelizumab | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Ocrelizumab is a CD20-directed cytolytic antibody indicated for the treatment of patients with primary progressive or relapsing forms of multiple sclerosis (MS). It is a second-generation recombinant humanized monoclonal IgG1 antibody that selectively targets B-cells that express the CD20 antigen. Compared to non-human... | Moderate | 1 | [
[
[
1532,
24,
270
]
],
[
[
1532,
63,
1461
],
[
1461,
23,
270
]
],
[
[
1532,
63,
134
],
[
134,
24,
270
]
],
[
[
1532,
24,
713
],
[
713,
... | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
... | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ocrelizumab
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelb... |
DB00564 | DB12001 | 1,236 | 564 | [
"DDInter293",
"DDInter7"
] | Carbamazepine | Abemaciclib | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Abemaciclib is an antitumor agent and dual inhibitor of cyclin-dependent kinases 4 (CDK4) and 6 (CDK6) that are involved in the cell cycle and promotion of cancer cell growth in case of unregulated activity. On September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the trea... | Major | 2 | [
[
[
1236,
25,
564
]
],
[
[
1236,
63,
1051
],
[
1051,
24,
564
]
],
[
[
1236,
25,
868
],
[
868,
24,
564
]
],
[
[
1236,
24,
392
],
[
392,
... | [
[
[
"Carbamazepine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abemaciclib"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aminoglutethimide"
],
[
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Abemaciclib
Carbamazepine may lead to a major life threatening interaction when taken with Vemurafenib and... |
DB06788 | DB13074 | 1,616 | 877 | [
"DDInter864",
"DDInter1110"
] | Histrelin | Macimorelin | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dep... | Major | 2 | [
[
[
1616,
25,
877
]
],
[
[
1616,
62,
112
],
[
112,
23,
877
]
],
[
[
1616,
63,
673
],
[
673,
24,
877
]
],
[
[
1616,
24,
1662
],
[
1662,
... | [
[
[
"Histrelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Histrelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidaz... | Histrelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Histrelin may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Ari... |
DB01244 | DB08868 | 762 | 1,011 | [
"DDInter192",
"DDInter737"
] | Bepridil | Fingolimod | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Multiple sclerosis, or MS, is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Fingolimod is a sphingosine 1-phosphate receptor modulator for the treatment of relapsing-remitting multiple sclerosis. It was developed by Novartis and initially appro... | Major | 2 | [
[
[
762,
25,
1011
]
],
[
[
762,
6,
12523
],
[
12523,
45,
1011
]
],
[
[
762,
21,
28792
],
[
28792,
60,
1011
]
],
[
[
762,
24,
578
],
[
578,... | [
[
[
"Bepridil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
]
],
[
[
"Bepridil",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fingolimod"... | Bepridil (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fingolimod (Compound)
Bepridil (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Fingolimod (Compound)
Bepridil may cause a moderate interaction that could exacerbate diseases when take... |
DB00865 | DB01246 | 939 | 820 | [
"DDInter187",
"DDInter45"
] | Benzphetamine | Alimemazine | A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222) | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
939,
24,
820
]
],
[
[
939,
1,
358
],
[
358,
24,
820
]
],
[
[
939,
24,
104
],
[
104,
40,
820
]
],
[
[
939,
24,
401
],
[
401,
24,
... | [
[
[
"Benzphetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Benzphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may caus... | Benzphetamine (Compound) resembles Orphenadrine (Compound) and Orphenadrine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine
Benzphetamine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimema... |
DB01177 | DB01244 | 77 | 762 | [
"DDInter904",
"DDInter192"
] | Idarubicin | Bepridil | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | A long-acting, non selective, calcium channel blocker with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist. It is no longer marketed in the United St... | Major | 2 | [
[
[
77,
25,
762
]
],
[
[
77,
63,
675
],
[
675,
40,
762
]
],
[
[
77,
6,
12523
],
[
12523,
45,
762
]
],
[
[
77,
7,
3588
],
[
3588,
45,... | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bepridil"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dext... | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Bepridil (Compound)
Idarubicin (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bepridil (Compound)
Idarubicin (Compound) upregulates TNNC1 (Gene) and TNN... |
DB00283 | DB01591 | 701 | 667 | [
"DDInter395",
"DDInter1696"
] | Clemastine | Solifenacin | An ethanolamine-derivative, first generation histamine H1 antagonist used in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness. | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
701,
24,
667
]
],
[
[
701,
6,
8374
],
[
8374,
45,
667
]
],
[
[
701,
21,
28786
],
[
28786,
60,
667
]
],
[
[
701,
24,
830
],
[
830,
... | [
[
[
"Clemastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Clemastine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)"... | Clemastine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Clemastine (Compound) causes Urinary retention (Side Effect) and Urinary retention (Side Effect) is caused by Solifenacin (Compound)
Clemastine may cause a moderate interaction that could exacerbate diseases when taken with P... |
DB00405 | DB01069 | 128 | 401 | [
"DDInter517",
"DDInter1533"
] | Dexbrompheniramine | Promethazine | Dexbrompheniramine maleate is an antihistamine agent that is used for the treatment of allergic conditions, such as hay fever or urticaria. | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Moderate | 1 | [
[
[
128,
24,
401
]
],
[
[
128,
24,
146
],
[
146,
24,
401
]
],
[
[
128,
24,
1264
],
[
1264,
63,
401
]
],
[
[
128,
40,
11439
],
[
11439,
... | [
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
]
],
[
[
"Dexbrompheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propiomaz... | Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine
Dexbrompheniramine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00023 | DB00099 | 305 | 440 | [
"DDInter127",
"DDInter735"
] | Asparaginase Escherichia coli | Filgrastim | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Filgrastim is a short-acting recombinant, non-pegylated human granulocyte colony-stimulating factor (G-CSF) analog produced by recombinant DNA technology. It has an amino acid sequence identical to endogenous G-CSF, but it is non-glycosylated unlike the endogenous G-CSF and has an N-terminal methionine added in the seq... | Moderate | 1 | [
[
[
305,
24,
440
]
],
[
[
305,
24,
37
],
[
37,
63,
440
]
],
[
[
305,
25,
1101
],
[
1101,
63,
440
]
],
[
[
305,
63,
1451
],
[
1451,
2... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Filgrastim"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Lomustine and Lomustine may cause a moderate interaction that could exacerbate diseases when taken with Filgrastim
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with ... |
DB01030 | DB08895 | 869 | 976 | [
"DDInter1835",
"DDInter1825"
] | Topotecan | Tofacitinib | An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I. | Tofacitinib is an inhibitor of Janus kinases, a group of intracellular enzymes involved in signalling pathways that affect hematopoiesis and immune cell function. It is approved by the FDA for treatment of moderate to severe rheumatoid arthritis that responds inadequately to methotrexate or in those who are intolerant ... | Major | 2 | [
[
[
869,
25,
976
]
],
[
[
869,
63,
1461
],
[
1461,
23,
976
]
],
[
[
869,
24,
214
],
[
214,
63,
976
]
],
[
[
869,
24,
868
],
[
868,
2... | [
[
[
"Topotecan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
]
],
[
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
... | Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Tofacitinib
Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamati... |
DB00054 | DB01381 | 1,432 | 958 | [
"DDInter6",
"DDInter819"
] | Abciximab | Ginkgo biloba | Abciximab is a Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) IIb/IIIa receptor of human platelets and inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules. It also binds to vitronectin (αv... | _Ginkgo biloba_ extract contains a group of terpene lactones (notably, ginkgolides and diterpenes) and ginkgo flavone glycosides (notably, ginkgetin, bilobetin, and sciadopitysin) that have antioxidant and vasoactive properties. Most of the studies that investigate the effect of _ginkgo biloba_ use the standardized ext... | Moderate | 1 | [
[
[
1432,
24,
958
]
],
[
[
1432,
25,
1347
],
[
1347,
24,
958
]
],
[
[
1432,
24,
121
],
[
121,
24,
958
]
],
[
[
1432,
64,
1271
],
[
1271,
... | [
[
[
"Abciximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ginkgo biloba"
]
],
[
[
"Abciximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidog... | Abciximab may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Ginkgo biloba
Abciximab may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may... |
DB00215 | DB11837 | 1,230 | 1,297 | [
"DDInter388",
"DDInter1351"
] | Citalopram | Osilodrostat | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] C... | Osilodrostat is an inhibitor of 11β-hydroxylase (also referred to as CYP11B1), the enzyme that catalyzes the final step in the biosynthesis of endogenous cortisol. It is used to lower circulating cortisol levels in the treatment of Cushing's disease, a disorder in which cortisol levels are chronically and supraphysiolo... | Major | 2 | [
[
[
1230,
25,
1297
]
],
[
[
1230,
23,
112
],
[
112,
23,
1297
]
],
[
[
1230,
25,
222
],
[
222,
23,
1297
]
],
[
[
1230,
24,
578
],
[
578,
... | [
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osilodrostat"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metroni... | Citalopram may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Osilodrostat
Citalopram may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may ... |
DB00374 | DB06081 | 1,061 | 1,046 | [
"DDInter1852",
"DDInter286"
] | Treprostinil | Caplacizumab | Treprostinil is a stable tricyclic analogue of prostacyclin that promotes the vasodilation of pulmonary and systemic arterial vascular beds and the inhibition of platelet aggregation.[L41855,L41860,L41865] It reduces symptoms in patients with pulmonary arterial hypertension (PAH) and pulmonary hypertension associated w... | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Moderate | 1 | [
[
[
1061,
24,
1046
]
],
[
[
1061,
23,
539
],
[
539,
62,
1046
]
],
[
[
1061,
24,
1039
],
[
1039,
24,
1046
]
],
[
[
1061,
1,
885
],
[
885,
... | [
[
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Caplacizumab"
]
],
[
[
"Treprostinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Capsicum"
],
[
... | Treprostinil may cause a minor interaction that can limit clinical effects when taken with Capsicum and Capsicum may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dex... |
DB00242 | DB06589 | 1,064 | 1,250 | [
"DDInter392",
"DDInter1400"
] | Cladribine | Pazopanib | An antineoplastic agent used in the treatment of lymphoproliferative diseases including hairy-cell leukemia. | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Major | 2 | [
[
[
1064,
25,
1250
]
],
[
[
1064,
6,
17404
],
[
17404,
45,
1250
]
],
[
[
1064,
7,
20113
],
[
20113,
46,
1250
]
],
[
[
1064,
6,
3293
],
[
3... | [
[
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pazopanib"
]
],
[
[
"Cladribine",
"{u} (Compound) binds {v} (Gene)",
"ABCG2"
],
[
"ABCG2",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"... | Cladribine (Compound) binds ABCG2 (Gene) and ABCG2 (Gene) is bound by Pazopanib (Compound)
Cladribine (Compound) upregulates IER3 (Gene) and IER3 (Gene) is upregulated by Pazopanib (Compound)
Cladribine (Compound) binds POLE2 (Gene) and POLE2 (Gene) is upregulated by Pazopanib (Compound)
Cladribine (Compound) binds RRM... |
DB00377 | DB01211 | 1,494 | 609 | [
"DDInter1382",
"DDInter393"
] | Palonosetron | Clarithromycin | Palonosetron (INN, trade name Aloxi) is an antagonist of 5-HT3 receptors that is indicated for the prevention and treatment of chemotherapy-induced nausea and vomiting (CINV). It is the most effective of the 5-HT3 antagonists in controlling delayed CINV nausea and vomiting that appear more than 24 hours after the first... | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Moderate | 1 | [
[
[
1494,
24,
609
]
],
[
[
1494,
63,
1570
],
[
1570,
24,
609
]
],
[
[
1494,
6,
8374
],
[
8374,
45,
609
]
],
[
[
1494,
21,
28759
],
[
28759... | [
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
]
],
[
[
"Palonosetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Azithromycin"
]... | Palonosetron may cause a moderate interaction that could exacerbate diseases when taken with Azithromycin and Azithromycin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin
Palonosetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Clarithromycin (Compound)
Pa... |
DB00342 | DB00477 | 1,181 | 216 | [
"DDInter1770",
"DDInter363"
] | Terfenadine | Chlorpromazine | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the tr... | Moderate | 1 | [
[
[
1181,
24,
216
]
],
[
[
1181,
24,
1178
],
[
1178,
1,
216
]
],
[
[
1181,
25,
684
],
[
684,
40,
216
]
],
[
[
1181,
24,
1237
],
[
1237,
... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluoperazine"
... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Trifluoperazine and Trifluoperazine (Compound) resembles Chlorpromazine (Compound)
Terfenadine may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine (Compound) resembles Chlorpromazine (C... |
DB00749 | DB12364 | 59 | 1,421 | [
"DDInter699",
"DDInter200"
] | Etodolac | Betrixaban | Etodolac is a non-steroidal anti-inflammatory drug (NSAID) with anti-inflammatory, analgesic and antipyretic properties. Its therapeutic effects are due to its ability to inhibit prostaglandin synthesis. It is indicated for relief of signs and symptoms of rheumatoid arthritis and osteoarthritis. | Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa . It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity . Betrixaban, now developed by Portola Pharmaceuticals ... | Major | 2 | [
[
[
59,
25,
1421
]
],
[
[
59,
24,
1039
],
[
1039,
24,
1421
]
],
[
[
59,
63,
305
],
[
305,
24,
1421
]
],
[
[
59,
24,
714
],
[
714,
25... | [
[
[
"Etodolac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
]
],
[
[
"Etodolac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenflu... | Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban
Etodolac may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Es... |
DB01035 | DB01177 | 1,401 | 77 | [
"DDInter1524",
"DDInter904"
] | Procainamide | Idarubicin | A derivative of procaine with less CNS action. | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Major | 2 | [
[
[
1401,
25,
77
]
],
[
[
1401,
6,
12523
],
[
12523,
45,
77
]
],
[
[
1401,
21,
28987
],
[
28987,
60,
77
]
],
[
[
1401,
62,
112
],
[
112,
... | [
[
[
"Procainamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
],
[
[
"Procainamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Ida... | Procainamide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Idarubicin (Compound)
Procainamide (Compound) causes Chills (Side Effect) and Chills (Side Effect) is caused by Idarubicin (Compound)
Procainamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Met... |
DB06605 | DB09065 | 1,409 | 760 | [
"DDInter108",
"DDInter424"
] | Apixaban | Cobicistat | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Cobicistat, marketed under the name Tybost (formerly GS-9350), indicated for treating infection with human immunodeficiency virus (HIV). Although it does not have any anti-HIV activity, cobicistat acts as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A isoforms (CYP3A) and therefore increases the systemic e... | Major | 2 | [
[
[
1409,
25,
760
]
],
[
[
1409,
63,
1230
],
[
1230,
23,
760
]
],
[
[
1409,
24,
555
],
[
555,
23,
760
]
],
[
[
1409,
24,
875
],
[
875,
... | [
[
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cobicistat"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Citalopram"
],
[
"Citalopram",
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Citalopram and Citalopram may cause a minor interaction that can limit clinical effects when taken with Cobicistat
Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Netupitant and Netupitant m... |
DB01611 | DB09564 | 1,487 | 1,296 | [
"DDInter893",
"DDInter930"
] | Hydroxychloroquine | Insulin degludec | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxyc... | Insulin degludec is an ultra-long-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes.[A18561,A18562,A18563,A18564,A174934] Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide horm... | Moderate | 1 | [
[
[
1487,
24,
1296
]
],
[
[
1487,
64,
17
],
[
17,
24,
1296
]
],
[
[
1487,
63,
1411
],
[
1411,
24,
1296
]
],
[
[
1487,
24,
659
],
[
659,
... | [
[
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
]
],
[
[
"Hydroxychloroquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
... | Hydroxychloroquine may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec
Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolb... |
DB00501 | DB00586 | 752 | 1,512 | [
"DDInter380",
"DDInter537"
] | Cimetidine | Diclofenac | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant ... | Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to inflammation and pain signalling. Diclofenac, like other NSAIDs, is often used as first... | Minor | 0 | [
[
[
752,
23,
1512
]
],
[
[
752,
23,
1263
],
[
1263,
63,
1512
]
],
[
[
752,
24,
1364
],
[
1364,
40,
1512
]
],
[
[
752,
6,
8374
],
[
8374,
... | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bromfenac"
],
[
"... | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bromfenac and Bromfenac may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Guanfacine and Guanfacine... |
DB00204 | DB01142 | 228 | 1,264 | [
"DDInter580",
"DDInter593"
] | Dofetilide | Doxepin | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepr... | Major | 2 | [
[
[
228,
25,
1264
]
],
[
[
228,
25,
401
],
[
401,
24,
1264
]
],
[
[
228,
6,
8374
],
[
8374,
45,
1264
]
],
[
[
228,
21,
28809
],
[
28809,
... | [
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
]
],
[
[
"Dofetilide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} ... | Dofetilide may lead to a major life threatening interaction when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin
Dofetilide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxepin (Compound)
Dofetilide (Compound) causes Diarrh... |
DB00295 | DB01591 | 475 | 667 | [
"DDInter1244",
"DDInter1696"
] | Morphine | Solifenacin | Morphine, the main alkaloid of opium, was first obtained from poppy seeds in 1805. It is a potent analgesic, though its use is limited due to tolerance, withdrawal, and the risk of abuse. Morphine is still routinely used today, though there are a number of semi-synthetic opioids of varying strength such as [codeine], [... | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
475,
24,
667
]
],
[
[
475,
6,
8374
],
[
8374,
45,
667
]
],
[
[
475,
21,
28743
],
[
28743,
60,
667
]
],
[
[
475,
24,
830
],
[
830,
... | [
[
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Morphine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Morphine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Morphine (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Morphine may cause a moderate interaction that could exacerbate diseases when taken with Phe... |
DB00731 | DB09046 | 1,144 | 1,094 | [
"DDInter1269",
"DDInter1201"
] | Nateglinide | Metreleptin | Nateglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Nateglinide is an amino acid derivative that ... | Metreleptin, a recombinant analog of the human hormone leptin, is an orphan drug used to treat complications of leptin deficiency in people with lipodystrophy. Lipodystrophies include a range of disorders characterized by the reduction, absence, or altered distribution of adipose tissue. Complications of lipodystrophy ... | Moderate | 1 | [
[
[
1144,
24,
1094
]
],
[
[
1144,
63,
168
],
[
168,
23,
1094
]
],
[
[
1144,
24,
959
],
[
959,
24,
1094
]
],
[
[
1144,
24,
517
],
[
517,
... | [
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metreleptin"
]
],
[
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[... | Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Metreleptin
Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipiz... |
DB00270 | DB00687 | 1,428 | 870 | [
"DDInter993",
"DDInter747"
] | Isradipine | Fludrocortisone | Isradipine belongs to the dihydropyridine (DHP) class of calcium channel blockers (CCBs), the most widely used class of CCBs. It is structurally related to felodipine, nifedipine, and nimodipine and is the most potent calcium-channel blocking agent of the DHP class. Isradipine binds to calcium channels with high affini... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
1428,
24,
870
]
],
[
[
1428,
24,
1220
],
[
1220,
40,
870
]
],
[
[
1428,
21,
28936
],
[
28936,
60,
870
]
],
[
[
1428,
24,
1040
],
[
104... | [
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Isradipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
... | Isradipine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Isradipine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Fludrocortisone (Compound)
Isradipine may cause... |
DB00262 | DB00987 | 552 | 1,224 | [
"DDInter302",
"DDInter461"
] | Carmustine | Cytarabine (liposomal) | A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogen... | Cytarabine can cause developmental toxicity according to an independent committee of scientific and health experts. | Moderate | 1 | [
[
[
552,
24,
1224
]
],
[
[
552,
5,
11555
],
[
11555,
44,
1224
]
],
[
[
552,
23,
872
],
[
872,
62,
1224
]
],
[
[
552,
23,
739
],
[
739,
... | [
[
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cytarabine"
]
],
[
[
"Carmustine",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Diseas... | Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Cytarabine
Carmustine (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Cytarabine (Compound)
Carmustine may cause a minor interaction that can limit clinical effects when taken with Ge... |
DB00443 | DB09104 | 251 | 286 | [
"DDInter195",
"DDInter1118"
] | Betamethasone | Magnesium hydroxide | Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and neg... | Magnesium hydroxide is an inorganic compound. It is naturally found as the mineral brucite. Magnesium hydroxide can be used as an antacid or a laxative in either an oral liquid suspension or chewable tablet form. Additionally, magnesium hydroxide has smoke suppressing and flame retardant properties and is thus used com... | Moderate | 1 | [
[
[
251,
24,
286
]
],
[
[
251,
24,
1482
],
[
1482,
23,
286
]
],
[
[
251,
63,
88
],
[
88,
23,
286
]
],
[
[
251,
23,
1382
],
[
1382,
2... | [
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
]
],
[
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digitoxin"
... | Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Digitoxin and Digitoxin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide
Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Metoprolol... |
DB00816 | DB04948 | 1,674 | 1,084 | [
"DDInter1346",
"DDInter1083"
] | Orciprenaline | Lofexidine | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
1674,
24,
1084
]
],
[
[
1674,
63,
618
],
[
618,
24,
1084
]
],
[
[
1674,
24,
774
],
[
774,
63,
1084
]
],
[
[
1674,
24,
688
],
[
688,
... | [
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
... | Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Lofexidine
Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degar... |
DB00414 | DB00945 | 590 | 1,479 | [
"DDInter16",
"DDInter20"
] | Acetohexamide | Acetylsalicylic acid | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Also known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial... | Moderate | 1 | [
[
[
590,
24,
1479
]
],
[
[
590,
24,
316
],
[
316,
40,
1479
]
],
[
[
590,
24,
1338
],
[
1338,
24,
1479
]
],
[
[
590,
63,
461
],
[
461,
... | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitazoxanid... | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Nitazoxanide and Nitazoxanide (Compound) resembles Acetylsalicylic acid (Compound)
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Meclofenamic acid and Meclofenamic acid may cause... |
DB00564 | DB09038 | 1,236 | 1,450 | [
"DDInter293",
"DDInter636"
] | Carbamazepine | Empagliflozin | Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbam... | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 dia... | Moderate | 1 | [
[
[
1236,
24,
1450
]
],
[
[
1236,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1236,
24,
1486
],
[
1486,
24,
1450
]
],
[
[
1236,
25,
1017
],
[
10... | [
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Carbamazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
... | Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Carbamazepine may cause a moderate interaction that could exacerbate diseases when taken with Methylpr... |
DB00373 | DB00687 | 461 | 870 | [
"DDInter1809",
"DDInter747"
] | Timolol | Fludrocortisone | Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective ag... | Fludrocortisone is a synthetic mineralocorticoid used in conjunction with [hydrocortisone] to replace missing endogenous corticosteroids in patients with adrenal insufficiency.[A187169,A187187] It is functionally similar to [aldosterone], the body's primary endogenous mineralocorticoid, and is structurally analogous to... | Moderate | 1 | [
[
[
461,
24,
870
]
],
[
[
461,
24,
1220
],
[
1220,
40,
870
]
],
[
[
461,
21,
28835
],
[
28835,
60,
870
]
],
[
[
461,
23,
115
],
[
115,
... | [
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
]
],
[
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
... | Timolol may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone (Compound) resembles Fludrocortisone (Compound)
Timolol (Compound) causes Hyperglycaemia (Side Effect) and Hyperglycaemia (Side Effect) is caused by Fludrocortisone (Compound)
Timolol may cause a mino... |
DB00352 | DB09074 | 482 | 1,362 | [
"DDInter1814",
"DDInter1327"
] | Tioguanine | Olaparib | An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Ol... | Moderate | 1 | [
[
[
482,
24,
1362
]
],
[
[
482,
24,
725
],
[
725,
63,
1362
]
],
[
[
482,
24,
896
],
[
896,
24,
1362
]
],
[
[
482,
63,
552
],
[
552,
... | [
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Satralizumab"
],
[
... | Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Satralizumab and Satralizumab may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etopo... |
DB00046 | DB01059 | 1,179 | 956 | [
"DDInter940",
"DDInter1313"
] | Insulin lispro | Norfloxacin | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | A synthetic fluoroquinolone (fluoroquinolones) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA gyrase. | Major | 2 | [
[
[
1179,
25,
956
]
],
[
[
1179,
25,
872
],
[
872,
40,
956
]
],
[
[
1179,
25,
1176
],
[
1176,
1,
956
]
],
[
[
1179,
24,
1491
],
[
1491,
... | [
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Norfloxacin"
]
],
[
[
"Insulin lispro",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",... | Insulin lispro may lead to a major life threatening interaction when taken with Gemifloxacin and Gemifloxacin (Compound) resembles Norfloxacin (Compound)
Insulin lispro may lead to a major life threatening interaction when taken with Moxifloxacin and Moxifloxacin (Compound) resembles Norfloxacin (Compound)
Insulin lisp... |
DB00656 | DB01362 | 827 | 497 | [
"DDInter1851",
"DDInter960"
] | Trazodone | Iohexol | Trazodone is triazolopyridine derivative from the serotonin receptor antagonists and reuptake inhibitors (SARIs) class of antidepressants. It is used in adults and has been shown to be comparable in efficacy to other drugs such as tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), and se... | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
827,
25,
497
]
],
[
[
827,
21,
28681
],
[
28681,
60,
497
]
],
[
[
827,
63,
999
],
[
999,
25,
497
]
],
[
[
827,
25,
1264
],
[
1264,
... | [
[
[
"Trazodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Trazodone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by ... | Trazodone (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Trazodone may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may lead to a major life threatening interaction when taken with I... |
DB00346 | DB06589 | 472 | 1,250 | [
"DDInter44",
"DDInter1400"
] | Alfuzosin | Pazopanib | Benign prostatic hyperplasia (BPH) refers to a benign growth or hyperplasia of the prostate and leads to lower urinary tract symptoms in men, such as urgency, frequency and changes to urine flow. The prevalence of BPH is as high as 50%-60% for males in their 60's, and this prevalence increases to 80%-90% of those over ... | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
472,
24,
1250
]
],
[
[
472,
6,
8374
],
[
8374,
45,
1250
]
],
[
[
472,
7,
4759
],
[
4759,
46,
1250
]
],
[
[
472,
21,
28658
],
[
28658,
... | [
[
[
"Alfuzosin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Alfuzosin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
... | Alfuzosin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Pazopanib (Compound)
Alfuzosin (Compound) upregulates SERPINA3 (Gene) and SERPINA3 (Gene) is upregulated by Pazopanib (Compound)
Alfuzosin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Pazopanib (Compound)
Alfuzosi... |
DB00208 | DB00959 | 1,018 | 1,486 | [
"DDInter1804",
"DDInter1191"
] | Ticlopidine | Methylprednisolone | Ticlopidine is an effective inhibitor of platelet aggregation. It is a prodrug that is metabolised to an active form, which blocks the ADP receptor that is involved in GPIIb/IIIa receptor activation leading to platelet aggregation. Ticlopidine is marketed under the brand name Ticlid and is indicated for patients who ca... | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was ... | Minor | 0 | [
[
[
1018,
23,
1486
]
],
[
[
1018,
23,
175
],
[
175,
40,
1486
]
],
[
[
1018,
23,
167
],
[
167,
1,
1486
]
],
[
[
1018,
6,
8374
],
[
8374,
... | [
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Triamcinolone"
],... | Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Me... |
DB01168 | DB01227 | 1,053 | 1,301 | [
"DDInter1526",
"DDInter1043"
] | Procarbazine | Levacetylmethadol | An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease. | Levacetylmethadol is a narcotic analgesic with a long onset and duration of action. It is used mainly in the treatment of narcotic dependence. Levacetylmethadol was withdrawn from use in the European Union due to its high risk of QT interval prolongation. The production of levacetylmethadol in the US has ceased as well... | Major | 2 | [
[
[
1053,
25,
1301
]
],
[
[
1053,
64,
675
],
[
675,
1,
1301
]
],
[
[
1053,
63,
146
],
[
146,
1,
1301
]
],
[
[
1053,
63,
1648
],
[
1648,
... | [
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
]
],
[
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextro... | Procarbazine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Levacetylmethadol (Compound)
Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Propiomazine and Propiomazine (Compound) resembles Levace... |
DB00983 | DB01261 | 480 | 170 | [
"DDInter776",
"DDInter1679"
] | Formoterol | Sitagliptin | Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major ... | Sitagliptin is an oral dipeptidyl peptidase-4 (DPP-4) inhibitor used in conjunction with diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus[FDA label,A2260,A2255,A2256]. The effect of this medication leads to glucose dependent increases in insulin and decreases in glucagon to improv... | Moderate | 1 | [
[
[
480,
24,
170
]
],
[
[
480,
21,
28850
],
[
28850,
60,
170
]
],
[
[
480,
24,
52
],
[
52,
62,
170
]
],
[
[
480,
24,
623
],
[
623,
2... | [
[
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sitagliptin"
]
],
[
[
"Formoterol",
"{u} (Compound) causes {v} (Side Effect)",
"Back pain"
],
[
"Back pain",
"{u} (Side Effect) is cau... | Formoterol (Compound) causes Back pain (Side Effect) and Back pain (Side Effect) is caused by Sitagliptin (Compound)
Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Dulaglutide and Dulaglutide may cause a minor interaction that can limit clinical effects when taken with Sitagl... |
DB06636 | DB09143 | 1,623 | 313 | [
"DDInter980",
"DDInter1701"
] | Isavuconazonium | Sonidegib | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is... | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Major | 2 | [
[
[
1623,
25,
313
]
],
[
[
1623,
63,
478
],
[
478,
24,
313
]
],
[
[
1623,
25,
1478
],
[
1478,
24,
313
]
],
[
[
1623,
24,
578
],
[
578,
... | [
[
[
"Isavuconazonium",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sonidegib"
]
],
[
[
"Isavuconazonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nilotinib"
],
[
"Ni... | Isavuconazonium may cause a moderate interaction that could exacerbate diseases when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Sonidegib
Isavuconazonium may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may c... |
DB01069 | DB01219 | 401 | 716 | [
"DDInter1533",
"DDInter473"
] | Promethazine | Dantrolene | Promethazine, originally known as 3,277 R.P., is an N-dimethylaminopropyl derivative of [phenothiazine] that was developed in France in 1946. Promethazine antagonizes a variety of receptors, allowing it to be used for a number of indications including allergic reactions, pain, sedation, nausea, and vomiting.[A189907,A1... | Chemically, dantrolene is a hydantoin derivative, but does not exhibit antiepileptic activity like other hydantoin derivates such as phenytoin. | Moderate | 1 | [
[
[
401,
24,
716
]
],
[
[
401,
21,
28698
],
[
28698,
60,
716
]
],
[
[
401,
24,
1609
],
[
1609,
63,
716
]
],
[
[
401,
63,
100
],
[
100,
... | [
[
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dantrolene"
]
],
[
[
"Promethazine",
"{u} (Compound) causes {v} (Side Effect)",
"Insomnia"
],
[
"Insomnia",
"{u} (Side Effect) is ca... | Promethazine (Compound) causes Insomnia (Side Effect) and Insomnia (Side Effect) is caused by Dantrolene (Compound)
Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Pentoxyverine and Pentoxyverine may cause a moderate interaction that could exacerbate diseases when taken with... |
DB00074 | DB05679 | 1,309 | 1,683 | [
"DDInter166",
"DDInter1907"
] | Basiliximab | Ustekinumab | A recombinant chimeric (murine/human) monoclonal antibody (IgG1k) that functions as an immunosuppressive agent, specifically binding to and blocking the interleukin-2 receptor a-chain (IL-2R alpha, also known as CD25 antigen) on the surface of activated T-lymphocytes. It is a 144 kDa glycoprotein obtained from fermenta... | Ustekinumab is a human immunoglobulin (Ig) G1 kappa monoclonal antibody directed against interleukin(IL)-12 and IL-23, which are cytokines that are involved in immune and inflammatory responses. It was generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. It is a targeted biologic dise... | Moderate | 1 | [
[
[
1309,
24,
1683
]
],
[
[
1309,
23,
1461
],
[
1461,
23,
1683
]
],
[
[
1309,
23,
1193
],
[
1193,
62,
1683
]
],
[
[
1309,
24,
1129
],
[
11... | [
[
[
"Basiliximab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
]
],
[
[
"Basiliximab",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vitamin E"
],
[
... | Basiliximab may cause a minor interaction that can limit clinical effects when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Ustekinumab
Basiliximab may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate and Zinc gl... |
DB00927 | DB06699 | 1,559 | 774 | [
"DDInter712",
"DDInter493"
] | Famotidine | Degarelix | Famotidine is a competitive histamine-2 (H<sub>2</sub>) receptor antagonist that works to inhibit gastric acid secretion. It is commonly used in gastrointestinal conditions related to acid secretion, such as gastric ulcers and gastroesophageal reflux disease (GERD), in adults and children. Compared to other H<sub>2</su... | Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone (GnRH) receptors in the pituitary gland and blocks interaction with GnRH. This antagonism reduces luteinising hormone (LH) and follicle-stimulating hormone (FSH... | Moderate | 1 | [
[
[
1559,
24,
774
]
],
[
[
1559,
63,
521
],
[
521,
1,
774
]
],
[
[
1559,
21,
29232
],
[
29232,
60,
774
]
],
[
[
1559,
62,
112
],
[
112,
... | [
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
]
],
[
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Goserelin"
],
[
... | Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Goserelin and Goserelin (Compound) resembles Degarelix (Compound)
Famotidine (Compound) causes Urticaria (Side Effect) and Urticaria (Side Effect) is caused by Degarelix (Compound)
Famotidine may cause a minor interaction that ca... |
DB00254 | DB00999 | 964 | 504 | [
"DDInter598",
"DDInter883"
] | Doxycycline | Hydrochlorothiazide | Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and... | Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and a... | Minor | 0 | [
[
[
964,
23,
504
]
],
[
[
964,
23,
1326
],
[
1326,
40,
504
]
],
[
[
964,
23,
178
],
[
178,
1,
504
]
],
[
[
964,
6,
10612
],
[
10612,
... | [
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Doxycycline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenamide"
]... | Doxycycline may cause a minor interaction that can limit clinical effects when taken with Diclofenamide and Diclofenamide (Compound) resembles Hydrochlorothiazide (Compound)
Doxycycline may cause a minor interaction that can limit clinical effects when taken with Polythiazide and Polythiazide (Compound) resembles Hydro... |
DB00762 | DB01226 | 613 | 1,319 | [
"DDInter973",
"DDInter1235"
] | Irinotecan | Mivacurium | Irinotecan is an antineoplastic enzyme inhibitor primarily used in the treatment of colorectal cancer. It is a derivative of camptothecin that inhibits the action of topoisomerase I. Irinotecan prevents religation of the DNA strand by binding to topoisomerase I-DNA complex, and causes double-strand DNA breakage and cel... | Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscular transmission. | Minor | 0 | [
[
[
613,
23,
1319
]
],
[
[
613,
23,
648
],
[
648,
1,
1319
]
],
[
[
613,
6,
10558
],
[
10558,
45,
1319
]
],
[
[
613,
21,
28921
],
[
28921,
... | [
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mivacurium"
]
],
[
[
"Irinotecan",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Doxacurium"
],
[
... | Irinotecan may cause a minor interaction that can limit clinical effects when taken with Doxacurium and Doxacurium (Compound) resembles Mivacurium (Compound)
Irinotecan (Compound) binds BCHE (Gene) and BCHE (Gene) is bound by Mivacurium (Compound)
Irinotecan (Compound) causes Dizziness (Side Effect) and Dizziness (Side... |
DB01182 | DB11110 | 371 | 603 | [
"DDInter1534",
"DDInter1115"
] | Propafenone | Magnesium citrate | An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity. The drug is generally well tolerated. | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Moderate | 1 | [
[
[
371,
24,
603
]
],
[
[
371,
64,
57
],
[
57,
24,
603
]
],
[
[
371,
24,
1616
],
[
1616,
24,
603
]
],
[
[
371,
24,
484
],
[
484,
63,... | [
[
[
"Propafenone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
]
],
[
[
"Propafenone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
... | Propafenone may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate
Propafenone may cause a moderate interaction that could exacerbate diseases when taken with Histrelin and H... |
DB00026 | DB12893 | 1,184 | 586 | [
"DDInter94",
"DDInter1629"
] | Anakinra | Sacituzumab govitecan | Anakinra is a recombinant human interleukin-1 (IL-1) receptor antagonist (IL-1Ra) composed of 153 amino acid residues. Unlike native human IL-1Ra, anakinra has an additional methionine residue at the amino terminus. This drug binds to the IL-1 receptor, competing with and inhibiting the activity of IL-1 alpha and beta.... | Metastatic triple-negative breast cancer (mTNBC) is an aggressive form of breast cancer with limited treatment options involving cytotoxic chemotherapy agents. Targeted chemotherapy through the application of antibody-conjugated agents (ADCs) is a recent advance in cancer treatment. One such ADC is sacituzumab goviteca... | Moderate | 1 | [
[
[
1184,
24,
586
]
],
[
[
1184,
24,
270
],
[
270,
24,
586
]
],
[
[
1184,
25,
1377
],
[
1377,
25,
586
]
],
[
[
1184,
24,
1619
],
[
1619,
... | [
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sacituzumab govitecan"
]
],
[
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
... | Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Sacituzumab govitecan
Anakinra may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide... |
DB00227 | DB01097 | 1,463 | 1,377 | [
"DDInter1098",
"DDInter1033"
] | Lovastatin | Leflunomide | Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disea... | Leflunomide is a pyrimidine synthesis inhibitor belonging to the DMARD (disease-modifying antirheumatic drug) class of drugs, which are chemically and pharmacologically very heterogeneous. Leflunomide was approved by FDA and in many other countries (e.g., Canada, Europe) in 1999. | Major | 2 | [
[
[
1463,
25,
1377
]
],
[
[
1463,
18,
8540
],
[
8540,
45,
1377
]
],
[
[
1463,
6,
6017
],
[
6017,
45,
1377
]
],
[
[
1463,
18,
17017
],
[
17... | [
[
[
"Lovastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
]
],
[
[
"Lovastatin",
"{u} (Compound) downregulates {v} (Gene)",
"DHODH"
],
[
"DHODH",
"{u} (Gene) is bound by {v} (Compound)",
"... | Lovastatin (Compound) downregulates DHODH (Gene) and DHODH (Gene) is bound by Leflunomide (Compound)
Lovastatin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Leflunomide (Compound)
Lovastatin (Compound) downregulates CD320 (Gene) and CD320 (Gene) is downregulated by Leflunomide (Compound)
Lovastatin (Com... |
DB01169 | DB11718 | 57 | 927 | [
"DDInter120",
"DDInter640"
] | Arsenic trioxide | Encorafenib | Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of danger... | Encorafenib, also known as _BRAFTOVI_, is a kinase inhibitor. Encorafenib inhibits BRAF gene, which encodes for B-raf protein, which is a proto-oncogene involved in various genetic mutations. This protein plays a role in regulating the MAP kinase/ERK signaling pathway, which impacts cell division, differentiation, and ... | Major | 2 | [
[
[
57,
25,
927
]
],
[
[
57,
62,
112
],
[
112,
23,
927
]
],
[
[
57,
24,
720
],
[
720,
24,
927
]
],
[
[
57,
64,
216
],
[
216,
24,
... | [
[
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
]
],
[
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Encorafenib
Arsenic trioxide may cause a moderate interaction that could exacerbate diseases when taken with Minera... |
DB00023 | DB00092 | 305 | 58 | [
"DDInter127",
"DDInter40"
] | Asparaginase Escherichia coli | Alefacept | Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginas... | Immunosuppressive dimeric fusion protein that consists of the extracellular CD2-binding portion of the human leukocyte function antigen-3 (LFA-3) linked to the Fc (hinge, CH2 and CH3 domains) portion of human IgG1. Produced by CHO cells, mW is 91.4 kD. | Moderate | 1 | [
[
[
305,
24,
58
]
],
[
[
305,
24,
304
],
[
304,
63,
58
]
],
[
[
305,
24,
1648
],
[
1648,
24,
58
]
],
[
[
305,
25,
375
],
[
375,
63,
... | [
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
]
],
[
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}... | Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Trimetrexate and Trimetrexate may cause a moderate interaction that could exacerbate diseases when taken with Alefacept
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate disea... |
DB00163 | DB01177 | 1,461 | 77 | [
"DDInter1943",
"DDInter904"
] | Vitamin E | Idarubicin | In 1922, vitamin E was demonstrated to be an essential nutrient. Vitamin E is a term used to describe 8 different fat soluble tocopherols and tocotrienols, alpha-tocopherol being the most biologically active. Vitamin E acts as an antioxidant, protecting cell membranes from oxidative damage. The antioxidant effects are ... | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1461,
24,
77
]
],
[
[
1461,
6,
5998
],
[
5998,
57,
77
]
],
[
[
1461,
24,
896
],
[
896,
24,
77
]
],
[
[
1461,
62,
66
],
[
66,
24,... | [
[
[
"Vitamin E",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Vitamin E",
"{u} (Compound) binds {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is downregulated by {v} (Compoun... | Vitamin E (Compound) binds HMOX1 (Gene) and HMOX1 (Gene) is downregulated by Idarubicin (Compound)
Vitamin E may cause a moderate interaction that could exacerbate diseases when taken with Etoposide and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Vitamin E may ca... |
DB01242 | DB06694 | 1,237 | 31 | [
"DDInter410",
"DDInter1952"
] | Clomipramine | Xylometazoline (nasal) | Clomipramine, the 3-chloro analog of imipramine, is a dibenzazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, clomipramine does not affect mood or aro... | Xylometazoline is an alkylbenzene. | Moderate | 1 | [
[
[
1237,
24,
31
]
],
[
[
1237,
6,
5372
],
[
5372,
45,
31
]
],
[
[
1237,
40,
1164
],
[
1164,
24,
31
]
],
[
[
1237,
24,
144
],
[
144,
... | [
[
[
"Clomipramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Xylometazoline"
]
],
[
[
"Clomipramine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Com... | Clomipramine may cause a moderate interaction that could exacerbate diseases when taken with Xylometazoline
Clomipramine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Xylometazoline (Compound)
Clomipramine (Compound) resembles Trimipramine (Compound) and Trimipramine may cause a moderate interaction that... |
DB01128 | DB06448 | 918 | 171 | [
"DDInter204",
"DDInter1087"
] | Bicalutamide | Lonafarnib | Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cut... | Major | 2 | [
[
[
918,
25,
171
]
],
[
[
918,
63,
254
],
[
254,
24,
171
]
],
[
[
918,
62,
112
],
[
112,
24,
171
]
],
[
[
918,
24,
850
],
[
850,
63,... | [
[
[
"Bicalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
],
[
[
"Bicalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisi... | Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and M... |
DB00757 | DB00780 | 1,166 | 551 | [
"DDInter581",
"DDInter1440"
] | Dolasetron | Phenelzine | Dolasetron is an antinauseant and antiemetic agent indicated for the prevention of nausea and vomiting associated with moderately-emetogenic cancer chemotherapy and for the prevention of postoperative nausea and vomiting. Dolasetron is a highly specific and selective serotonin 5-HT3 receptor antagonist. This drug is no... | Phenelzine, with the formula β-phenylethylhydrazine, is a monoamine oxidase inhibiting antidepressant that is effective in the treatment of panic disorder and social anxiety disorder. It was developed by Parke Davis and originally FDA approved on June 9th, 1961. It is currently approved under prescription by the name o... | Major | 2 | [
[
[
1166,
25,
551
]
],
[
[
1166,
25,
633
],
[
633,
40,
551
]
],
[
[
1166,
6,
8374
],
[
8374,
45,
551
]
],
[
[
1166,
21,
28827
],
[
28827,
... | [
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenelzine"
]
],
[
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
... | Dolasetron may lead to a major life threatening interaction when taken with Lisdexamfetamine and Lisdexamfetamine (Compound) resembles Phenelzine (Compound)
Dolasetron (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Phenelzine (Compound)
Dolasetron (Compound) causes Orthostatic hypotension (Side Effect) an... |
DB00682 | DB00833 | 126 | 1,305 | [
"DDInter1951",
"DDInter309"
] | Warfarin | Cefaclor | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be not... | Semisynthetic, broad-spectrum antibiotic derivative of cephalexin. | Moderate | 1 | [
[
[
126,
24,
1305
]
],
[
[
126,
24,
1124
],
[
1124,
40,
1305
]
],
[
[
126,
63,
1087
],
[
1087,
40,
1305
]
],
[
[
126,
63,
1145
],
[
1145,
... | [
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefaclor"
]
],
[
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cefamandole"
],
[
"... | Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefamandole and Cefamandole (Compound) resembles Cefaclor (Compound)
Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Cefotaxime and Cefotaxime (Compound) resembles Cefaclor (Compound)
Warfar... |
DB00518 | DB08899 | 510 | 129 | [
"DDInter35",
"DDInter649"
] | Albendazole | Enzalutamide | A benzimidazole broad-spectrum anthelmintic structurally related to mebendazole that is effective against many diseases. (From Martindale, The Extra Pharmacopoeia, 30th ed, p38) | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Moderate | 1 | [
[
[
510,
24,
129
]
],
[
[
510,
6,
8374
],
[
8374,
45,
129
]
],
[
[
510,
21,
28921
],
[
28921,
60,
129
]
],
[
[
510,
62,
608
],
[
608,
... | [
[
[
"Albendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Albendazole",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compoun... | Albendazole (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Albendazole (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Enzalutamide (Compound)
Albendazole may cause a minor interaction that can limit clinical effects when taken with Lidocaine and ... |
DB00675 | DB06176 | 888 | 1,342 | [
"DDInter1744",
"DDInter1616"
] | Tamoxifen | Romidepsin | Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment ... | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
888,
24,
1342
]
],
[
[
888,
23,
1247
],
[
1247,
23,
1342
]
],
[
[
888,
24,
956
],
[
956,
24,
1342
]
],
[
[
888,
24,
1616
],
[
1616,
... | [
[
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Tamoxifen",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
... | Tamoxifen may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Romidepsin
Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Norfloxacin and... |
DB00647 | DB00986 | 675 | 1,192 | [
"DDInter528",
"DDInter834"
] | Dextropropoxyphene | Glycopyrronium | Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the mar... | Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its ... | Moderate | 1 | [
[
[
675,
24,
1192
]
],
[
[
675,
24,
1511
],
[
1511,
63,
1192
]
],
[
[
675,
35,
262
],
[
262,
24,
1192
]
],
[
[
675,
21,
29231
],
[
29231,
... | [
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glycopyrronium"
]
],
[
[
"Dextropropoxyphene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzo... | Dextropropoxyphene may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium
Dextropropoxyphene (Compound) resembles Clidinium (Compound) and Dextropropoxyphene may cause a mo... |
DB08826 | DB11817 | 1,292 | 1,259 | [
"DDInter489",
"DDInter165"
] | Deferiprone | Baricitinib | Deferiprone is an oral iron chelator used as a second line agent in thalassemia syndromes when iron overload from blood transfusions occurs. Thalassemias are a type of hereditary anaemia due a defect in the production of hemoglobin. As a result, erythropoiesis, the production of new red blood cells, is impaired. FDA ap... | Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are tyrosine protein kinases that play an important role in pro-inflammatory signaling pathways. Overactive JAKs have been implicated in autoimmune disorders, such as rheumatoid arthritis. By inhibiting the actions of JAK1 and JAK2, baricitinib attenuates JAK-mediated... | Major | 2 | [
[
[
1292,
25,
1259
]
],
[
[
1292,
24,
1193
],
[
1193,
23,
1259
]
],
[
[
1292,
64,
563
],
[
563,
24,
1259
]
],
[
[
1292,
63,
1512
],
[
1512... | [
[
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
]
],
[
[
"Deferiprone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zinc gluconate"
],
[
"Zin... | Deferiprone may cause a moderate interaction that could exacerbate diseases when taken with Zinc gluconate and Zinc gluconate may cause a minor interaction that can limit clinical effects when taken with Baricitinib
Deferiprone may lead to a major life threatening interaction when taken with Ganciclovir and Ganciclovir... |
DB01085 | DB04843 | 562 | 1,511 | [
"DDInter1465",
"DDInter1149"
] | Pilocarpine | Mepenzolate | A naturally occurring alkaloid derived from the _Pilocarpus_ plants, pilocarpine is a muscarinic acetylcholine agonist.[A262016, A262036] Pilocarpine is associated with parasympathomimetic effects by selectively working on muscarinic receptors. Pilocarpine is used to treat dry mouth and various ophthalmic conditions, i... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
562,
24,
1511
]
],
[
[
562,
24,
537
],
[
537,
24,
1511
]
],
[
[
562,
63,
1192
],
[
1192,
24,
1511
]
],
[
[
562,
24,
1429
],
[
1429,
... | [
[
[
"Pilocarpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Pilocarpine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Pilocarpine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Pilocarpine may cause a moderate interaction that could exacerbate diseases when taken with Glycopyrronium and G... |
DB00621 | DB09228 | 1,026 | 687 | [
"DDInter1357",
"DDInter437"
] | Oxandrolone | Conestat alfa | A synthetic hormone with anabolic and androgenic properties. | C1 Esterase Inhibitor (Recombinant) is a recombinant analogue of endogenous complement component-1 esterase inhibitor (rhC1INH), purified from the milk of transgenic rabbits. The primary function of endogenous C1INH is to regulate the activation of the complement and contact system pathways. It does this through inhibi... | Moderate | 1 | [
[
[
1026,
24,
687
]
],
[
[
1026,
40,
1561
],
[
1561,
24,
687
]
],
[
[
1026,
25,
350
],
[
350,
25,
687
]
],
[
[
1026,
40,
1561
],
[
1561,
... | [
[
[
"Oxandrolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conestat alfa"
]
],
[
[
"Oxandrolone",
"{u} (Compound) resembles {v} (Compound)",
"Testosterone"
],
[
"Testosterone",
"{u} may cause ... | Oxandrolone (Compound) resembles Testosterone (Compound) and Testosterone may cause a moderate interaction that could exacerbate diseases when taken with Conestat alfa
Oxandrolone may lead to a major life threatening interaction when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interactio... |
DB08896 | DB11760 | 292 | 119 | [
"DDInter1576",
"DDInter1742"
] | Regorafenib | Talazoparib | Regorafenib is an orally-administered inhibitor of multiple kinases. It is used for the treatment of metastatic colorectal cancer, advanced gastrointestinal stromal tumours, and hepatocellular carcinoma. FDA approved on September 27, 2012. Approved use of Regorafenib was expanded to treat Hepatocellular Carcinoma in Ap... | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was app... | Moderate | 1 | [
[
[
292,
24,
119
]
],
[
[
292,
63,
441
],
[
441,
24,
119
]
],
[
[
292,
25,
1339
],
[
1339,
63,
119
]
],
[
[
292,
24,
214
],
[
214,
6... | [
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Regorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Delavirdine"
],
... | Regorafenib may cause a moderate interaction that could exacerbate diseases when taken with Delavirdine and Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Regorafenib may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat m... |
DB01033 | DB06643 | 328 | 1,136 | [
"DDInter1156",
"DDInter500"
] | Mercaptopurine | Denosumab | An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia. | Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of osteoclasts. It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.... | Moderate | 1 | [
[
[
328,
24,
1136
]
],
[
[
328,
63,
1555
],
[
1555,
24,
1136
]
],
[
[
328,
74,
482
],
[
482,
24,
1136
]
],
[
[
328,
24,
1532
],
[
1532,
... | [
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Denosumab"
]
],
[
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
... | Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Denosumab
Mercaptopurine (Compound) resembles Tioguanine (Compound) and Mercaptopurine may cause a moderate interacti... |
DB05812 | DB08899 | 1,374 | 129 | [
"DDInter8",
"DDInter649"
] | Abiraterone | Enzalutamide | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 201... | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line ... | Major | 2 | [
[
[
1374,
25,
129
]
],
[
[
1374,
6,
8374
],
[
8374,
45,
129
]
],
[
[
1374,
21,
29044
],
[
29044,
60,
129
]
],
[
[
1374,
62,
1247
],
[
1247... | [
[
[
"Abiraterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
]
],
[
[
"Abiraterone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enz... | Abiraterone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Abiraterone (Compound) causes Pneumonia (Side Effect) and Pneumonia (Side Effect) is caused by Enzalutamide (Compound)
Abiraterone may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazo... |
DB00556 | DB00816 | 1,262 | 1,674 | [
"DDInter1429",
"DDInter1346"
] | Perflutren | Orciprenaline | Perflutren, a diagnostic drug that is intended to be used for contrast enhancement during the indicated echocardiographic procedures, is comprised of lipid-coated microspheres filled with octafluoropropane(OFP) gas. When exposed to ultrasound waves, the microspheres resonate and "echo" strong signals back to the ultras... | A beta-adrenergic agonist used in the treatment of asthma and bronchospasms. [PubChem] | Moderate | 1 | [
[
[
1262,
24,
1674
]
],
[
[
1262,
21,
28921
],
[
28921,
60,
1674
]
],
[
[
1262,
63,
618
],
[
618,
24,
1674
]
],
[
[
1262,
24,
484
],
[
484... | [
[
[
"Perflutren",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
]
],
[
[
"Perflutren",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is c... | Perflutren (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Orciprenaline (Compound)
Perflutren may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Orcipren... |
DB00046 | DB15093 | 1,179 | 1,654 | [
"DDInter940",
"DDInter1698"
] | Insulin lispro | Somapacitan | Insulin lispro is a rapid-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promote... | Somapacitan, also known as NNC0195-0092, is a growth hormone analog indicated to treat adults with growth hormone deficiency.[A219126,L15661] This human growth hormone analog differs by the creation of an albumin binding site, and prolonging the effect so that it requires weekly dosing rather than daily. Somapacitan wa... | Moderate | 1 | [
[
[
1179,
24,
1654
]
],
[
[
1179,
24,
168
],
[
168,
23,
1654
]
],
[
[
1179,
24,
433
],
[
433,
24,
1654
]
],
[
[
1179,
24,
1101
],
[
1101,
... | [
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somapacitan"
]
],
[
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],... | Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somapacitan
Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Ertugliflozin ... |
DB06228 | DB12267 | 792 | 1,476 | [
"DDInter1609",
"DDInter233"
] | Rivaroxaban | Brigatinib | Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be t... | Brigatinib, originally named AP26113, is a reversible dual inhibitor of anaplastic lymphoma kinase (ALK) and epidermal growth factor receptor (EGFR). It presents selectivity against the mutant forms of EGFR compared to the wild-type. It also exhibits selectivity against 9 different Crizotinib-resistant mutants of the E... | Moderate | 1 | [
[
[
792,
24,
1476
]
],
[
[
792,
24,
1612
],
[
1612,
23,
1476
]
],
[
[
792,
63,
1184
],
[
1184,
24,
1476
]
],
[
[
792,
24,
800
],
[
800,
... | [
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
]
],
[
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[... | Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Brigatinib
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakin... |
DB00086 | DB06081 | 1,167 | 1,046 | [
"DDInter1712",
"DDInter286"
] | Streptokinase | Caplacizumab | Streptokinase, is a sterile, purified preparation of a bacterial protein elaborated by group C (beta) -hemolytic streptococci. | Caplacizumab, firstly called ALX-0081, is a humanized single-variable-domain immunoglobulin consisting of two identical humanized building blocks genetically linked by a three-alanine linker. Caplacizumab was developed by Ablynx, a Sanofi company and FDA approved on February 6, 2019, and approved previously by the EU i... | Major | 2 | [
[
[
1167,
25,
1046
]
],
[
[
1167,
23,
1631
],
[
1631,
62,
1046
]
],
[
[
1167,
24,
222
],
[
222,
24,
1046
]
],
[
[
1167,
24,
1427
],
[
1427... | [
[
[
"Streptokinase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
]
],
[
[
"Streptokinase",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Turmeric"
],
[
"Turmer... | Streptokinase may cause a minor interaction that can limit clinical effects when taken with Turmeric and Turmeric may cause a minor interaction that can limit clinical effects when taken with Caplacizumab
Streptokinase may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibut... |
DB00631 | DB01083 | 372 | 1,142 | [
"DDInter405",
"DDInter1348"
] | Clofarabine | Orlistat | Clofarabine is a purine nucleoside antimetabolite that is being studied in the treatment of cancer. It is marketed as Clolar in the U.S. and Canada, or Evoltra in Europe, Australia, and New Zealand. Clofarabine is used in paediatrics to treat a type of leukaemia called relapsed or refractory acute lymphoblastic leukaem... | The global prevalence of obesity is increasing rapidly. Obesity-related complications lead to significant personal and economic burden by reducing quality of life and increasing the cost of healthcare. In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical inter... | Moderate | 1 | [
[
[
372,
24,
1142
]
],
[
[
372,
18,
13123
],
[
13123,
46,
1142
]
],
[
[
372,
7,
1720
],
[
1720,
46,
1142
]
],
[
[
372,
21,
28645
],
[
2864... | [
[
[
"Clofarabine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orlistat"
]
],
[
[
"Clofarabine",
"{u} (Compound) downregulates {v} (Gene)",
"ELOVL6"
],
[
"ELOVL6",
"{u} (Gene) is upregulated by {v... | Clofarabine (Compound) downregulates ELOVL6 (Gene) and ELOVL6 (Gene) is upregulated by Orlistat (Compound)
Clofarabine (Compound) upregulates RELB (Gene) and RELB (Gene) is upregulated by Orlistat (Compound)
Clofarabine (Compound) causes Cough (Side Effect) and Cough (Side Effect) is caused by Orlistat (Compound)
Clofa... |
DB00593 | DB09098 | 1,464 | 98 | [
"DDInter695",
"DDInter1700"
] | Ethosuximide | Somatrem | An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disp... | Moderate | 1 | [
[
[
1464,
24,
98
]
],
[
[
1464,
24,
159
],
[
159,
63,
98
]
],
[
[
1464,
24,
222
],
[
222,
24,
98
]
],
[
[
1464,
63,
506
],
[
506,
24... | [
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Ethosuximide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
... | Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Ethosuximide may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine a... |
DB00286 | DB01011 | 380 | 925 | [
"DDInter439",
"DDInter1204"
] | Conjugated estrogens | Metyrapone | The conjugated estrogens are noncrystalline mixtures of purified female sex hormones obtained either by its isolation from the urine of pregnant mares or by synthetic generation from vegetal material. Both of these products are later conjugated to natrium sulfate by ester bonds in order to make them more water soluble.... | An inhibitor of the enzyme steroid 11-beta-monooxygenase. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of cushing syndrome. | Moderate | 1 | [
[
[
380,
24,
925
]
],
[
[
380,
6,
16319
],
[
16319,
45,
925
]
],
[
[
380,
21,
28766
],
[
28766,
60,
925
]
],
[
[
380,
40,
890
],
[
890,
... | [
[
[
"Conjugated estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metyrapone"
]
],
[
[
"Conjugated estrogens",
"{u} (Compound) binds {v} (Gene)",
"ABCC3"
],
[
"ABCC3",
"{u} (Gene) is bound b... | Conjugated estrogens (Compound) binds ABCC3 (Gene) and ABCC3 (Gene) is bound by Metyrapone (Compound)
Conjugated estrogens (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Metyrapone (Compound)
Conjugated estrogens (Compound) resembles Mestranol (Compound) and Mestranol may cause a... |
DB09407 | DB13997 | 853 | 133 | [
"DDInter1114",
"DDInter163"
] | Magnesium chloride | Baloxavir marboxil | Magnesium chloride salts are highly soluble in water and the hydrated form of magnesium chloride can be extracted from brine or sea water. | Baloxavir marboxil is an antiviral drug used to treat influenza. More specifically, it is a first-in-class cap-dependent endonuclease inhibitor that works to block influenza virus proliferation.[A39895, A251755] It is a prodrug of [baloxavir] with an improved absorption profile than its active metabolite due to the add... | Moderate | 1 | [
[
[
853,
24,
133
]
],
[
[
853,
63,
544
],
[
544,
24,
133
]
],
[
[
853,
24,
460
],
[
460,
24,
133
]
],
[
[
853,
63,
544
],
[
544,
24,... | [
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Baloxavir marboxil"
]
],
[
[
"Magnesium chloride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mag... | Magnesium chloride may cause a moderate interaction that could exacerbate diseases when taken with Magnesium sulfate and Magnesium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Baloxavir marboxil
Magnesium chloride may cause a moderate interaction that could exacerbate diseases... |
DB00372 | DB01618 | 999 | 776 | [
"DDInter1793",
"DDInter1239"
] | Thiethylperazine | Molindone | A dopamine antagonist that is particularly useful in treating the nausea and vomiting associated with anesthesia, mildly emetic cancer chemotherapy agents, radiation therapy, and toxins. This piperazine phenothiazine does not prevent vertigo or motion sickness. (From AMA Drug Evaluations Annual, 1994, p457) | An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to mo... | Moderate | 1 | [
[
[
999,
24,
776
]
],
[
[
999,
24,
100
],
[
100,
24,
776
]
],
[
[
999,
24,
1662
],
[
1662,
63,
776
]
],
[
[
999,
63,
1594
],
[
1594,
... | [
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Molindone"
]
],
[
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brompheniramine"... | Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Brompheniramine and Brompheniramine may cause a moderate interaction that could exacerbate diseases when taken with Molindone
Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB06589 | DB06788 | 1,250 | 1,616 | [
"DDInter1400",
"DDInter864"
] | Pazopanib | Histrelin | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-con... | Moderate | 1 | [
[
[
1250,
24,
1616
]
],
[
[
1250,
62,
112
],
[
112,
23,
1616
]
],
[
[
1250,
63,
1664
],
[
1664,
24,
1616
]
],
[
[
1250,
24,
603
],
[
603,
... | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Histrelin"
]
],
[
[
"Pazopanib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
... | Pazopanib may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Histrelin
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Risperidone and Risper... |
DB11110 | DB12245 | 603 | 823 | [
"DDInter1115",
"DDInter1863"
] | Magnesium citrate | Triclabendazole | Magnesium citrate is a low volume and osmotic cathartic agent. The cathartic action works primarily through the high osmolarity of the solution which draws large amounts of fluid into space where is used. Magnesium citrate is considered by the FDA as an approved inactive ingredient for approved drug products under the ... | Triclabendazole, manufactured by Novartis pharmaceuticals, is an antihelminthic drug that was approved by the FDA in February 2019 for the treatment of fascioliasis in humans.[FDA label, L5452] Fascioliasis is a parasitic infection often caused by the helminth, _Fasciola hepatica_, which is also known as “the common li... | Moderate | 1 | [
[
[
603,
24,
823
]
],
[
[
603,
24,
1612
],
[
1612,
24,
823
]
],
[
[
603,
63,
1010
],
[
1010,
24,
823
]
],
[
[
603,
24,
180
],
[
180,
... | [
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
]
],
[
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsa... | Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole
Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with ... |
DB06605 | DB08867 | 1,409 | 807 | [
"DDInter108",
"DDInter1897"
] | Apixaban | Ulipristal | Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FD... | Ulipristal is a selective progesterone receptor modulator used for the purposes of emergency contraception (Ella) and for the treatment of uterine fibroids (Fibristal). It is a derivative of 19-norprogesterone and has both antagonistic and partial agonist activity at the progesterone receptor. It also binds to glucocor... | Moderate | 1 | [
[
[
1409,
24,
807
]
],
[
[
1409,
63,
600
],
[
600,
23,
807
]
],
[
[
1409,
64,
792
],
[
792,
24,
807
]
],
[
[
1409,
24,
1017
],
[
1017,
... | [
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ulipristal"
]
],
[
[
"Apixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
... | Apixaban may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Apixaban may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a ... |
DB00421 | DB01246 | 443 | 820 | [
"DDInter1707",
"DDInter45"
] | Spironolactone | Alimemazine | Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were disco... | A phenothiazine derivative that is used as an antipruritic. | Moderate | 1 | [
[
[
443,
24,
820
]
],
[
[
443,
24,
104
],
[
104,
40,
820
]
],
[
[
443,
24,
401
],
[
401,
24,
820
]
],
[
[
443,
21,
29956
],
[
29956,
... | [
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
]
],
[
[
"Spironolactone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
... | Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine and Methdilazine (Compound) resembles Alimemazine (Compound)
Spironolactone may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate inter... |
DB01211 | DB04948 | 609 | 1,084 | [
"DDInter393",
"DDInter1083"
] | Clarithromycin | Lofexidine | Clarithromycin, a semisynthetic macrolide antibiotic derived from erythromycin, inhibits bacterial protein synthesis by binding to the bacterial 50S ribosomal subunit. Binding inhibits peptidyl transferase activity and interferes with amino acid translocation during the translation and protein assembly process. Clarith... | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hyp... | Moderate | 1 | [
[
[
609,
24,
1084
]
],
[
[
609,
62,
112
],
[
112,
23,
1084
]
],
[
[
609,
63,
618
],
[
618,
24,
1084
]
],
[
[
609,
24,
774
],
[
774,
... | [
[
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lofexidine"
]
],
[
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],... | Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Lofexidine
Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Abarelix an... |
DB01067 | DB04865 | 959 | 4 | [
"DDInter826",
"DDInter1335"
] | Glipizide | Omacetaxine mepesuccinate | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guide... | Omacetaxine mepesuccinate (formerly known as HHT or Homoharringtonine), is a cephalotaxine ester and protein synthesis inhibitor with established clinical activity as a single agent in hematological malignancies. Omacetaxine mepesuccinate is synthesized from cephalotaxine, which is an extract from the leaves of the pla... | Moderate | 1 | [
[
[
959,
24,
4
]
],
[
[
959,
18,
3833
],
[
3833,
46,
4
]
],
[
[
959,
18,
7247
],
[
7247,
57,
4
]
],
[
[
959,
63,
485
],
[
485,
24,
... | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
]
],
[
[
"Glipizide",
"{u} (Compound) downregulates {v} (Gene)",
"JMJD6"
],
[
"JMJD6",
"{u} (Gene) is upregu... | Glipizide (Compound) downregulates JMJD6 (Gene) and JMJD6 (Gene) is upregulated by Omacetaxine mepesuccinate (Compound)
Glipizide (Compound) downregulates NPDC1 (Gene) and NPDC1 (Gene) is downregulated by Omacetaxine mepesuccinate (Compound)
Glipizide may cause a moderate interaction that could exacerbate diseases when... |
DB00445 | DB00543 | 322 | 87 | [
"DDInter655",
"DDInter82"
] | Epirubicin | Amoxapine | An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA. | Amoxapine, the <i>N</i>-demethylated derivative of the antipsychotic agent loxapine, is a dibenzoxazepine-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, am... | Moderate | 1 | [
[
[
322,
24,
87
]
],
[
[
322,
24,
623
],
[
623,
40,
87
]
],
[
[
322,
64,
695
],
[
695,
40,
87
]
],
[
[
322,
63,
867
],
[
867,
1,
... | [
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amoxapine"
]
],
[
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quetiapine"
],
[
... | Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Quetiapine and Quetiapine (Compound) resembles Amoxapine (Compound)
Epirubicin may lead to a major life threatening interaction when taken with Clozapine and Clozapine (Compound) resembles Amoxapine (Compound)
Epirubicin may caus... |
DB06210 | DB11986 | 72 | 484 | [
"DDInter631",
"DDInter648"
] | Eltrombopag | Entrectinib | Eltrombopag is used to treat low blood platelet counts in adults with chronic immune (idiopathic) thrombocytopenia (ITP), when certain other medicines, or surgery to remove the spleen, have not worked well enough. ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelet... | Entrectinib is a tropomyosin receptor tyrosine kinase (TRK) TRKA, TRKB, TRKC, proto-oncogene tyrosine-protein kinase ROS1, and anaplastic lymphoma kinase (ALK) inhibitor. It was approved by the FDA in August 2019 for use in the treatment of ROS1-positive metastatic non-small cell lung cancer and NTRK gene fusion positi... | Moderate | 1 | [
[
[
72,
24,
484
]
],
[
[
72,
24,
466
],
[
466,
62,
484
]
],
[
[
72,
63,
322
],
[
322,
24,
484
]
],
[
[
72,
24,
603
],
[
603,
24,
... | [
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
]
],
[
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
... | Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Entrectinib
Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and E... |
DB00342 | DB11796 | 1,181 | 1,612 | [
"DDInter1770",
"DDInter786"
] | Terfenadine | Fostemsavir | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Fostemsavir is the phosphonooxymethyl prodrug of temsavir, a novel HIV-1 attachment inhibitor. It binds to and inhibits the activity of gp120, a subunit within the HIV-1 gp160 envelope glycoprotein that facilitates the attachment of HIV-1 to host cell CD4 receptors - in doing so, temsavir prevents the first step in the... | Moderate | 1 | [
[
[
1181,
24,
1612
]
],
[
[
1181,
24,
1476
],
[
1476,
62,
1612
]
],
[
[
1181,
63,
1101
],
[
1101,
23,
1612
]
],
[
[
1181,
24,
1040
],
[
10... | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[... | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may cause a minor interaction that can limit clinical effects when taken with Fostemsavir
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexar... |
DB00056 | DB01041 | 816 | 770 | [
"DDInter814",
"DDInter1789"
] | Gemtuzumab ozogamicin | Thalidomide | Gemtuzumab ozogamicin is a recombinant humanized IgG4 kappa antibody which is conjugated with calicheamicin derivative, a cytotoxic antitumor antibiotic isolated from fermentation of Micromonospora echinospora ssp. calichensis. Gemtuzumab ozogamicin has approximately 50% of the antibody loaded with 4-6 moles calicheami... | A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, thalidomide was withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of inflammatory disorders and cancers. Thalidomide displays immunosuppressive and anti-angiogenic activity through modulating ... | Major | 2 | [
[
[
816,
25,
770
]
],
[
[
816,
24,
4
],
[
4,
63,
770
]
],
[
[
816,
23,
739
],
[
739,
24,
770
]
],
[
[
816,
24,
563
],
[
563,
24,
... | [
[
[
"Gemtuzumab ozogamicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
]
],
[
[
"Gemtuzumab ozogamicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuc... | Gemtuzumab ozogamicin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide
Gemtuzumab ozogamicin may cause a minor interaction that can limit cli... |
DB00734 | DB04843 | 1,664 | 1,511 | [
"DDInter1605",
"DDInter1149"
] | Risperidone | Mepenzolate | Risperidone is a second-generation antipsychotic (SGA) medication used in the treatment of a number of mood and mental health conditions including schizophrenia and bipolar disorder. It is one of the most widely used SGAs. [Paliperidone], another commonly used SGA, is the primary active metabolite of risperidone (i.e. ... | Mepenzolate is a post-ganglionic parasympathetic inhibitor. It decreases gastric acid and pepsin secretion and suppresses spontaneous contractions of the colon. Mepenzolate diminishes gastric acid and pepsin secretion. Mepenzolate also suppresses spontaneous contractions of the colon. Pharmacologically, it is a post-ga... | Moderate | 1 | [
[
[
1664,
24,
1511
]
],
[
[
1664,
24,
537
],
[
537,
24,
1511
]
],
[
[
1664,
63,
352
],
[
352,
24,
1511
]
],
[
[
1664,
24,
649
],
[
649,
... | [
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepenzolate"
]
],
[
[
"Risperidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
... | Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine may cause a moderate interaction that could exacerbate diseases when taken with Mepenzolate
Risperidone may cause a moderate interaction that could exacerbate diseases when taken with Trospium and Trospiu... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.